Paper-Analytical Device for Saliva Biomarker Diagnostics

项目摘要： 心力衰竭（HF）每年影响美国570万人，其中1/9的死亡与该疾病有关。 在护理点测量诊断和预后生物标志物是减少HF相关死亡的关键， 侵入性的基于血液的诊断测试需要大量的资源并且昂贵。对敏感的关键需求 利用非侵入性样品的测定仍然是护理点诊断的迫切需要。在这里，我们建议 开发一种创新的解决方案来快速、灵敏且廉价地测量唾液中的生物标志物， 与HF有关。为了满足这一需求，一种基于纸张的分析设备（PAD），结合唾液样本 用敏感的电化学生物传感器处理，以检测半乳糖凝集素-3（Gal-3）和s100 A7作为 唾液中会出现HF。该项目包括两个目标，1）展示一个敏感的，选择性的， 用于s100 A7和Gal-3的电化学PAD，和2）开发可快速和有效地处理 不同粘度的唾液该项目是亨利集团与 科罗拉多州立大学（CSU）和昆士兰州科技大学（QUT）的Punyadeera小组 在澳大利亚国际合作是合理的，因为亨利集团在PAD和 Punyadeera小组在唾液诊断方面有经验。一旦成功，我们将扩大双方的数量 以及心血管疾病和头颈癌的生物标志物类型。我们还将准备扩大 正在进行的基于唾液的生物标志物的临床研究，以进一步验证其作为非侵入性生物标志物的用途。

Project Summary: Heart failure (HF) affects 5.7M people annually in the United States with 1 in 9 deaths linked to the disorder. Measuring diagnostic and prognostic biomarkers at the point of care is key for reducing HF-related deaths but invasive blood-based diagnostic tests require extensive resources and are expensive. A critical need for sensitive assays that utilize non-invasive samples remains a pressing need for point-of-care diagnostics. Here, we propose to develop an innovative solution to rapid, sensitive, and inexpensive measurements of biomarkers in saliva that are correlated with HF. To address this need, a paper-based analytic device (PAD) that combines saliva sample processing with sensitive electrochemical biosensors to detect galectin-3 (Gal-3) and s100A7 as biomarkers of HF in saliva will be developed. The project consists of two aims, 1) demonstration of a sensitive, selective electrochemical PAD for s100A7 and Gal-3 and 2) development of a PAD that can rapidly and efficiently process saliva of varying viscosities in minutes. This project is an international collaboration between the Henry group at Colorado State University (CSU) and the Punyadeera group at the Queensland University of Technology (QUT) in Australia. The international collaboration is justified because the Henry group has expertise in PADs and the Punyadeera group has experience with saliva-based diagnostics. Once successful, we will expand both the number and type of biomarkers for both cardiovascular disease and head/neck cancers. We will also be poised to expand on-going clinical studies of saliva-based biomarkers to further validate their use as non-invasive biomarkers.